JB Chemicals & Pharmaceuticals is currently trading at Rs. 302.70, up by 4.30 points or 1.44% from its previous closing of Rs. 298.40 on the BSE.
The scrip opened at Rs. 303.80 and has touched a high and low of Rs. 308.25 and Rs. 302.55 respectively. So far 7,700 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 367.65 on 02-Feb-2017 and a 52 week low of Rs. 255.00 on 28-Sep-2017.
Last one week high and low of the scrip stood at Rs. 308.25 and Rs. 292.05 respectively. The current market cap of the company is Rs. 2,521.72 crore.
The promoters holding in the company stood at 55.85%, while Institutions and Non-Institutions held 14.20% and 29.95% respectively.
JB Chemicals & Pharmaceuticals has received USFDA approval for its Supplementary Abbreviated New Drug Application (sANDA) for Atenolol Tablets USP 25 mg. 50 mg. and 100 mg. (anti-hypertensive) manufactured using Company’s own bulk drug (API). The company had initiated this change as a part of its plan to gradually backward integrate US formulations business. This approval is expected to boost company’s US sales.
The company could not commercialize this formulation earlier due to problems associated with external API supplier. This approval will help company supply these formulations with its own API. The company plans to commercialize this product in the next quarter. Currently, the market for this product in US is about $70 million. The company is focused on US business and this approval will help grow its exports.
JB Chemicals & Pharmaceuticals (JBCPL) is engaged in manufacturing of pharmaceutical specialties in various dosage forms, herbal remedies, diagnostics, generic drugs, active pharmaceutical ingredients (APIs).
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1797.80 |
| Dr. Reddys Lab | 1215.35 |
| Cipla | 1486.25 |
| Lupin | 2072.60 |
| Zydus Lifesciences | 947.05 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Claim your FREE 15-day access to the most practical investing handbook.
Hurry, limited to the first 10 users today!
Become a savvy and confident
stock investor.
Don't miss out! First 10 users today get it FREE
Download APP
